{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000990","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.463272+00:00","generated_at":"2026-05-31T13:11:25.251530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track","bullets":["Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.","Net loss $17.2M ($0.64 per share) improved from $52.6M loss in Q2 2023.","Cash $317.2M; cash runway extends through Q1 2027; $437.1M received from CSL to date.","IND submitted for ARCT-032 Phase 2 cystic fibrosis study; ARCT-810 OTC deficiency interim data expected Q4 2024.","Kostaive on track for Q4 commercial launch in Japan; EMA review ongoing; COVID/flu programs with CSL progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000990","json":"https://secwatch.observer/filing/0001193805-24-000990.json","markdown":"https://secwatch.observer/filing/0001193805-24-000990.md","text":"https://secwatch.observer/filing/0001193805-24-000990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000990/0001193805-24-000990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000990/e663815_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:11:25.251530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}